Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Baker

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Journal of Professional Nursing : Official Journal of the American Association of Colleges of Nursing|July 1, 1997
Organizational effectiveness: toward an integrated model for schools of nursingC M Baker, D L Reising, D R Johnson, et al.
British Journal of Cancer|August 30, 2012
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsE Chatelut, M L White-Koning, R Hj Mathijssen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic studyE K Rowinsky, S D Baker, K Burks, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumorsS D Baker, R L Heideman, W R Crom, et al.
British Journal of Cancer|May 14, 2008
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100N F Smith, S D Baker, F J Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicityC F Stewart, S D Baker, R L Heideman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemiaW L Furman, S D Baker, C B Pratt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 28, 2004
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapyM A Rudek, A Sparreboom, E S Garrett-Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignanciesJ Gilbert, S D Baker, M K Bowling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2008
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignanciesA Jimeno, W A Messersmith, C K Lee, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Journal of Professional Nursing : Official Journal of the American Association of Colleges of Nursing|July 1, 1997
Organizational effectiveness: toward an integrated model for schools of nursingC M Baker, D L Reising, D R Johnson, et al.
British Journal of Cancer|August 30, 2012
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsE Chatelut, M L White-Koning, R Hj Mathijssen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic studyE K Rowinsky, S D Baker, K Burks, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumorsS D Baker, R L Heideman, W R Crom, et al.
British Journal of Cancer|May 14, 2008
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100N F Smith, S D Baker, F J Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicityC F Stewart, S D Baker, R L Heideman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemiaW L Furman, S D Baker, C B Pratt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 28, 2004
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapyM A Rudek, A Sparreboom, E S Garrett-Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignanciesJ Gilbert, S D Baker, M K Bowling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2008
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignanciesA Jimeno, W A Messersmith, C K Lee, et al.
Pageof 7